Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Actinogen Medical (ACW)

Latest price

AUD0.02

— 0.00 (0.00)

As at 28/11/2023

Market capitalisation: AUD38m

View equity

mingwei-lim-QxGSSfatjRs-unsplash-1024x1024

Update

Healthcare

25.10.23

Actinogen Medical — Taking steps to mitigate funding headwinds

edison tv

Healthcare

27.09.23

Actinogen Medical – executive interview

Update

Healthcare

10.08.23

NZD3.35

— 0.00 (0.00)

As at 28/11/2023

Market capitalisation: NZD345m

View equity

Update

Healthcare

27.11.23

AFT Pharmaceuticals — Global growth despite tough macro environment

Flash note

Healthcare

19.10.23

AFT Pharmaceuticals — FDA nod for opioid alternative, upside anticipated

Flash note

Healthcare

31.08.23

CHF35.10

▾ −0.70 (−1.96)

As at 28/11/2023

Market capitalisation: CHF470m

View equity

misael-moreno-fN6K30xtiKE-unsplash-Basilea

Flash note

Healthcare

14.11.23

Basilea Pharmaceutica — Incremental acquisition to arsenal; new guidance

edison tv

Healthcare

09.11.23

Basilea Pharmaceutica – executive interview

Flash note

Healthcare

01.11.23

USD5.11

▾ 1.61 (46.00)

As at 28/11/2023

Market capitalisation: USD2m

View equity

Flash note

Healthcare

24.05.23

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline

Update

Healthcare

16.05.23

Biodexa Pharmaceuticals — Pivoting out of a challenging FY22

Flash note

Healthcare

28.03.23

SEK3.57

▾ 0.01 (0.28)

As at 28/11/2023

Market capitalisation: SEK689m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK0.67

▾ 0.02 (3.08)

As at 28/11/2023

Market capitalisation: SEK46m

View equity

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

RhoVac — On the home straight

Outlook

Healthcare

14.10.21

GBP0.32

▾ −0.40 (−1.23)

As at 28/11/2023

Market capitalisation: GBP117m

View equity

Flash note

Healthcare

03.11.23

Creo Medical — FDA nod for UltraSlim

Flash note

Healthcare

26.10.23

Creo Medical — Potential UltraSlim upside with swift EU pathway

Update

Healthcare

14.09.23

GBP0.10

▾ −0.78 (−7.48)

As at 28/11/2023

Market capitalisation: GBP62m

View equity

Update

Healthcare

13.11.23

e-therapeutics — More to come in RNAi therapy discovery

Initiation

Healthcare

16.05.23

USD5.01

▾ 0.61 (13.86)

As at 28/11/2023

Market capitalisation: USD83m

View equity

Flash note

Healthcare

22.11.23

Immix Biopharma — CAR-T trial moves to US with outpatient potential

Update

Healthcare

17.11.23

Immix Biopharma — A quarter of progress for both lead assets

Update

Healthcare

10.10.23

USD1.08

▾ 0.16 (17.39)

As at 28/11/2023

Market capitalisation: USD54m

View equity

insight

Healthcare

28.11.23

Incannex’s US redomicile is now complete – what’s next?

insight

Healthcare

20.07.23

Incannex Healthcare: Is life better on Nasdaq?

Update

Healthcare

01.06.23

SEK6.72

▾ 0.10 (1.51)

As at 28/11/2023

Market capitalisation: SEK350m

View equity

edison tv

Healthcare

08.11.23

IRLAB Therapeutics – executive interview

Update

Healthcare

27.10.23

IRLAB Therapeutics — Quarterly update recapping active pipeline plans

Flash note

Healthcare

10.10.23

SEK0.60

▾ 0.03 (5.26)

As at 28/11/2023

Market capitalisation: SEK417m

View equity

edison tv

Healthcare

27.11.23

Mendus – executive interview

Update

Healthcare

13.11.23

Mendus — Guarding against relapse

Flash note

Healthcare

02.11.23

USD3.03

▾ 0.28 (10.18)

As at 28/11/2023

Market capitalisation: USD107m

View equity

edison tv

Healthcare

20.04.23

MindMed update on major depressive disorder data: Rob Barrow, CEO

edison tv

Healthcare

29.03.23

MindMed - executive interview with Dan Karlin, CMO

edison tv

Healthcare

22.02.23

PLN16.78

▾ −0.02 (−0.12)

As at 28/11/2023

Market capitalisation: PLN243m

View equity

Update

Healthcare

06.11.23

Molecure — Q323 report highlights clinical progress

Update

Healthcare

04.10.23

Molecure — Striving to maximise clinical potential

Update

Healthcare

27.07.23

CHF4.76

▾ 0.53 (12.53)

As at 28/11/2023

Market capitalisation: CHF86m

View equity

insight

Healthcare

20.11.23

Newron Pharmaceuticals: EKF 2023 QuickView

Update

Healthcare

11.10.23

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Update

Healthcare

07.08.23

EUR0.39

▾ −0.02 (−4.88)

As at 28/11/2023

Market capitalisation: EUR21m

View equity

Update

Healthcare

14.11.23

Nicox — Q323 update confirms trajectory for NCX-470

Flash note

Healthcare

21.07.23

Nicox — Denali trial remains on track for 2025 readout

Flash note

Healthcare

13.07.23

Nicox — Nicox provides NCX-470 sales potential estimates

See more
content on

Nicox

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity Strategy and Market outlook – October 2023

Equity strategy and market outlook – September 2023

Equity strategy and market outlook – August 2023

Thematics

Latest

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

Deutsches Eigenkapitalforum (EKF) 2023 technology

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.02

Actinogen Medical — Taking steps to mitigate funding headwinds

Actinogen Medical – executive interview

Actinogen Medical — Funding the next stage of Xanamem development

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.35

AFT Pharmaceuticals — Global growth despite tough macro environment

AFT Pharmaceuticals — FDA nod for opioid alternative, upside anticipated

AFT Pharmaceuticals — AFTO judgment clears AFT of breach claim

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF35.10

Basilea Pharmaceutica — Incremental acquisition to arsenal; new guidance

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Growth pivot with potential antibacterial addition

See morecontent on

Biodexa Pharmaceuticals (BDRX)

USD5.11

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline

Biodexa Pharmaceuticals — Pivoting out of a challenging FY22

Midatech Pharma — Development pipeline expands with MTD217

See morecontent on

Cantargia (CANTA)

SEK3.57

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Chosa (CHOSA)

SEK0.67

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

RhoVac — Phase IIb BRaVac study results in H122

See morecontent on

Creo Medical (CREO)

GBP0.32

Creo Medical — FDA nod for UltraSlim

Creo Medical — Potential UltraSlim upside with swift EU pathway

Creo Medical — Detailed half-yearly reflecting Speedboat traction

See morecontent on

e-therapeutics (ETX)

GBP0.10

e-therapeutics — More to come in RNAi therapy discovery

e-therapeutics — Enhancing siRNA drug discovery with LLMs

See morecontent on

Immix Biopharma (IMMX)

USD5.01

Immix Biopharma — CAR-T trial moves to US with outpatient potential

Immix Biopharma — A quarter of progress for both lead assets

Immix Biopharma — A step toward delivering a practical CAR-T option

See morecontent on

Incannex Healthcare (IXHL)

USD1.08

Incannex’s US redomicile is now complete – what’s next?

Incannex Healthcare: Is life better on Nasdaq?

Incannex Healthcare — Spotlight on Incannex’s progress in psychedelics

See morecontent on

IRLAB Therapeutics (IRLABA)

SEK6.72

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Quarterly update recapping active pipeline plans

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on